John P. Bilezikian, MD, the Dorothy L. and Daniel H. Silberberg Professor of Medicine and Professor of Pharmacology at the College of Physicians & Surgeons, Columbia University is Chief of the Division of Endocrinology and Director of the Metabolic Bone Diseases Program at Columbia University Medical Center. Dr. Bilezikian received his undergraduate training at Harvard College and his medical training at the College of Physicians & Surgeons. He completed four years of house staff training (internship, residency and Chief Residency) on the Medical Service at Columbia Presbyterian Medical Center. Dr. Bilezikian received his training in Metabolic Bone Diseases and in Endocrinology at the NIH in the Mineral Metabolism Branch under the tutelage of Dr. Gerald Aurbach. Dr. Bilezikian belongs to a number of professional societies including the American Society for Bone and Mineral Research, of which he served as President, 1995-1996 and the International Society of Clinical Densitometry, of which he served as President, 1999-2001. He serves on the Board of Governors of the International Osteoporosis Foundation (1998-present) and on its Committee of Scientific Advisors (2001-present). He is Chair of the Endocrine Fellows Foundation. He served as Editor-in-Chief of the Journal of Clinical Endocrinology and Metabolism (2000-2004) and as Senior Associate Editor of the Journal of Bone and Mineral Research (2008-2012). He is Executive Advisory Editor of Bone Research (2013-present). His books include Editor-in-Chief of The Parathyroids [1994, 2001, 2014], and co-editor of The Aging Skeleton (1999), Dynamics of Bone and Cartilage Metabolism (1999, 2006), Principles of Bone Biology (1996, 2002, 2008) and Osteoporosis in Men (2010). He served as co-chair of the last three NIH Workshops on Primary Hyperparathyroidism (2002, 2008, 2013). He is the recipient of the Distinguished Physician Award of the Endocrine Society, the Frederic C. Bartter Award of the American Society for Bone and Mineral Research (ASBMR) for Excellence in Clinical Research and the First Annual Global Leadership Award of the International Society of Clinical Densitometry. In 2009, he received the Gideon A. Rodan Excellence in Mentorship Award from the ASBMR. He received the Laureate Distinguished Educator Award of The Endocrine Society in 2014. In 2014, he was made honorary member of the Brazilian Society of Endocrinology and Metabolism. His publications number over 700. Dr. Raisz is Professor of Medicine and Program Director of the General Clinical Research Center at the University of Connecticut Health Center. He has been carrying out laboratory and clinical studies in the field of osteoporosis and bone metabolism for over 40 years. He has mentored a large number of investigators in these areas both here at the University of Connecticut and previously at the University of Rochester School of Medicine. His current studies include an analysis of the effects of estrogen and androgen on the expression of cytokines and growth factors in bone, which is being carried out in both humans and animal models, studies of the role of prostaglandins in bone metabolism using transgenic mice, studies on the effects of progestins on bone turnover in postmenopausal women and tissue culture and animal studies on new antiresorptive and anabolic agents carried out in collaboration with the pharmaceutical industry. Dr. Martin has served on 12 state and national committees and boards, been an international lecturer for nearly 20 years, and his work has been extensively published in a total of 420 original papers, 178 reviews, chapters and editorials, and seven books. He was appointed as Officer of the Order of Australia, elected to fellowships of the Australian Academy and the Royal Society and received 12 prestigious career awards, including the Eric Susman Prize from the Royal Australasian College of Physician. He has had 12 patents granted and held eight international visiting appointments in the United Kingdom, United States, and Switzerland. An outstanding contribution to science includes the cloning of parathyroid hormone related protein.
